share_log

Barclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $329

Benzinga ·  Nov 1 21:46  · Ratings

Barclays analyst Gena Wang maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the price target from $295 to $329.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment